Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Jennifer R. Brown et al.|New England Journal of Medicine|2014Cited by 1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, Arthur L. Shaffer et al.|Nature Medicine|2015Cited by 1.1k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Bonnie K. Harrington et al.|New England Journal of Medicine|2015Cited by 890
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed<i>/</i>Refractory MyelofibrosisJohn Mascarenhas, Maciej Kaźmierczak, Viola Maria Popov et al.|Blood|2024Cited by 15